1. Health Strategies Group
Key Finding #1
7/20/2018
Health Strategies Group
Author/Artist
Evolving Market Dynamics Will Continue to Influence and Limit Access to Branded Diabetes Drugs by 2019
Availability of new brands and biosimilars, along with potential entrance of multisource generics, will compel stakeholders to intensify management tactics to further narrow access to preferred branded diabetes drugs.
Biopharmaceutical companies that support stakeholder objectives of achieving high-quality, cost- effective long-term care for diabetes patients will likely achieve or sustain optimal access for their brands.
To request slides